Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
NCT03899259Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2019
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 10
01
Overview
A Phase 3 trial of baricitinib in alopecia areata, sponsored by Eli Lilly and Company. Started Jul 2019; status: completed.
02
Drugs
baricitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT03899259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899259.